Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide/formoterol - Pearl Therapeutics

Drug Profile

Budesonide/formoterol - Pearl Therapeutics

Alternative Names: BFF MDI; Budesonide and formoterol (BFF MDI) - Pearl Therapeutics; Formoterol/budesonide - Pearl Therapeutics; PT-009

Latest Information Update: 03 Mar 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pearl Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 10 Sep 2019 Phase-III clinical trials in Chronic obstructive pulmonary disease (Treatment-experienced) in Germany (Inhalation) (NCT04078126)
  • 04 Sep 2019 AstraZeneca plans a phase III trial for Chronic obstructive pulmonary disease (Treatment-experienced) in Germany in September 2019 (Inhalation) (NCT04078126)
  • 17 May 2019 Updated efficacy and pharmacokinetics data from the phase III KRONOS trial in Chronic obstructive pulmonary disease presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top